Development and Validation of a Thallium Flux-Based Functional Assay for the Sodium Channel NaV1.7 and Its Utility for Lead Discovery and Compound Profiling

ACS Chemical Neuroscience

Volumn 6, Issue 6, 2015, Pages 871-878

  Du, Yu ^a   Days, Emily ^a   Romaine, Ian ^a   Abney, Kris K ^a,b   Kaufmann, Kristian ^a   Sulikowski, Gary ^a   Stauffer, Shaun ^a   Lindsley, Craig W ^a   Weaver, C David ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

drug discovery; High throughput screening; sodium channel; thallium flux

Indexed keywords

BUPIVACAINE; CARBAMAZEPINE; CID 6044366; LIDOCAINE; MCFD 00168650; MIBEFRADIL; PHENOLPHTHALEIN; RANOLAZINE; SODIUM CHANNEL NAV1.7; TETRODOTOXIN; THALLIUM; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT; VU 0464120; SODIUM CHANNEL BLOCKING AGENT; VERATRIDINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE; FLUX ASSAY; HEK293 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; VALIDATION PROCESS; VOLTAGE CLAMP TECHNIQUE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; METABOLISM; PATCH CLAMP TECHNIQUE; PROCEDURES; VALIDATION STUDY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PATCH-CLAMP TECHNIQUES; SODIUM CHANNEL BLOCKERS; THALLIUM; VERATRIDINE;

EID: 84935034858     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00004     Document Type: Article

References (50)

1. Clare, J.-J. (2010) Targeting Ion Channels for Drug Discovery Discovery Med. 9, 253-260
2. Wickenden, A., Priest, B., and Erdemli, G. (2012) Ion channel drug discovery: challenges and future directions Future Med. Chem. 4, 661-679
3. Terstappen, G.-C., Roncarati, R., Dunlop, J., and Peri, R. (2010) Screening technologies for ion channel drug discovery Future Med. Chem. 2, 715-730
4. Clark, J.-M. and Symington, S.-B. (2011) Advances in the Mode of Action of Pyrethroids Top. Curr. Chem. 314, 49-72
5. Casida, J.-E. (2011) Curious about pesticide action J. Agric. Food Chem. 59, 2762-2769
6. Casida, J.-E. and Durkin, K.-A. (2013) Neuroactive insecticides: targets, selectivity, resistance, and secondary effects Annu. Rev. Entomol. 2013, 99-117
7. Bagal, S.-K., Brown, A.-D., Cox, P.-J., Omoto, K., Owen, R.-M., Pryde, D.-C., Sidders, B., Skerratt, S.-E., Stevens, E.-B., Storer, I.-R., and Swain, N.-A. (2013) Ion Channels as Therapeutic Targets: A Drug Discovery Perspective J. Med. Chem. 56, 593-624
8. Jegla, T.-J., Zmasek, C.-M., Batalov, S., and Nayak, S.-K. (2009) Evolution of the human ion channel set Comb. Chem. High Throughput Screen 12, 2-23
9. Klassen, T., Davis, C., Goldman, A., Burgess, D., Chen, T., Wheeler, D., McPherson, J., Bourquin, T., Lewis, L., Villasana, D., Morgan, M., Muzny, D., Gibbs, R., and Noebels, J. (2011) Exome sequencing of ion channel genes reveals complex profiles confounding personal risk assessment in epilepsy Cell 145, 1036-1048
10. Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D., and Arias, R. (2008) High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology Nat. Rev. Drug Discovery 7, 358-368
11. Farre, C., Stoelzle, S., Haarmann, C., George, M., Brüggemann, A., and Fertig, N. (2007) Automated ion channel screening: patch clamping made easy Expert Opin. Ther. Targets 11, 557-565
12. Castle, N., Printzenhoff, D., Zellmer, S., Antonio, B., Wickenden, A., and Silvia, C. (2009) Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms Comb. Chem. High Throughput Screening 12, 107-122
13. Lubin, M.-L., Reitz, T.-L., Todd, M.-J., Flores, C.-M., Qin, N., and Xin, H. (2006) A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye Assay Drug Dev. Technol. 4, 689-694
14. Kim, Y., Kang, S., Lee, J.-Y., and Rhim, H. (2009) High throughput screening assay of alpha(1G) T-type Ca2+ channels and comparison with patch-clamp studies. Comb. Chem High Throughput Screening 12, 296-302
15. Xie, X., Van Deusen, A.-L., Vitko, I., Babu, D.-A., Davies, L.-A., Huynh, N., Cheng, H., Yang, N., Barrett, P.-Q., and Perez-Reyes, E. (2007) Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches Assay Drug Dev. Technol. 5, 191-203
16. Bettini, E., Sava, A., Griffante, C., Carignani, C., Buson, A., Capelli, A.-M., Negri, M., Andreetta, F., Senar-Sancho, S.-A., Guiral, L., and Cardullo, F. (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors J. Pharmacol. Exp. Ther. 335, 636-644
17. Kaufmann, K., Romaine, I., Days, E., Pascual, C., Malik, A., Yang, L., Zou, B., Du, Y., Sliwoski, G., Morrison, R.-D., Denton, J., Niswender, C.-M., Daniels, J.-S., Sulikowski, G.-A., Xie, X.-S., Lindsley, C. W., and Weaver, C.-D. (2013) ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice ACS Chem. Neurosci. 4, 1278-1286
18. Raphemot, R., Lonergan, D.-F., Nguyen, T.-T., Utley, T., Lewis, L. M., Kadakia, R., Weaver, C.-D., Gogliotti, R., Hopkins, C., Lindsley, C.-W., and Denton, J.-S. (2011) Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1 Front. Pharmacol. 2, 75
19. Wydeven, N., Fernandez de Velasco, E.-M., Du, Y., Benneyworth, M.-A., Hearing, M.-C., Fischer, R.-A., Thomas, M.-J., Weaver, C.-D., and Wickman, K. (2014) Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297 Proc. Natl. Acad. Sci. U. S. A. 111, 10755-10760
20. Yu, H., Wu, M., Townsend, S.-D., Zou, B., Long, S., Daniels, J.-S., McManus, O.-B., Li, M., Lindsley, C.-W., and Hopkins, C.-R. (2011) Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener ACS Chem. Neurosci. 2, 572-577
21. Weaver, C.-D., Harden, D., Dworetzky, S.-I., Robertson, B., and Knox, R.-J. (2004) A Thallium-sensitive, Fluorescence-based Assay for Detecting and Characterizing Potassium Channel Modulators in Mammalian Cells J. Biomol. Screen. 9, 671-677
22. Niswender, C.-M., Myers, K.-A., Lou, Q., Ayala, J., Kim, C., Conn, P.-J., and Weaver, C.-D. (2008) Development of a Novel and Direct Assay for High-Throughput Screening of Gi/o-linked GPCRs using Thallium Flux Through GIRK Channels J. Mol. Pharm. 73, 1213-1224
23. Lewis, M., Bhave, G., Chauder, B.-A., Banerjee, S., Lornsen, K., Redha, R., Fallen, K., Lindsley, C.-W., Weaver, C.-D., and Denton, J.-S. (2009) High-throughput screening reveals a small-molecule inhibitor of ROMK and Kir7.1 Mol. Pharmacol. 76, 1094-103
24. Bhave, G., Chauder, B. A., Liu, W., Dawson, E. S., Kadakia, R., Nguyen, T.-T., Lewis, L.-M., Meiler, J., Weaver, C.-D., Satlin, L.-M., Lindsley, C.-W., and Denton, J.-S. (2010) Development of a selective small-molecule inhibitor of Kir1.1, the Renal Outer Medullary Potassium Channel Mol. Pharmacol. 79, 42-50
25. Potet, F., Lorinc, A.-N., Chaigne, S., Hopkins, C.-R., Venkataraman, R., Stepanovic, S.-Z., Lewis, L.-M., Days, E., Sidorov, V.-Y., Engers, D.-W., Zou, B., Afshartous, D., George, A.-L., Jr., Campbell, C.-M., Balser, J.-R., Li, M., Baudenbacher, F.-J., Lindsley, C.-W., Weaver, C.-D., and Kupershmidt, S. (2012) Identification and characterization of a compound that protects cardiac tissue from human ether-a-go-go-related gene (hERG)-related, drug-induced Arrhythmias J. Biol. Chem. 287, 39613-39625
26. Li, Q., Rottländer, M., Xu, M., Christoffersen, C.-T., Frederiksen, K., Wang, M.-W., and Jensen, H.-S. (2011) Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay Anal. Biochem. 418, 66-72
27. Schmalhofer, W.-A., Swensen, A.-M., Thomas, B.-S., Felix, J.-P., Haedo, R.-J., Solly, K., Kiss, L., Kaczorowski, G.-J., and Garcia, M.-L. (2010) A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel Assay Drug Dev. Technol. 8, 714-726
28. Delpire, E.-J., Days, E., Lewis, M., Mi, D., Lindsley, C., and Weaver, C.-D. (2009) Small Molecule Screen Identifies Novel Inhibitors of the Neuronal K-Cl cotransporter KCC2 Proc. Natl. Acad. Sci. U. S. A. 106, 5383-5388
29. Carmosino, M., Rizzo, F., Torretta, S., Procino, G., and Svelto, M. (2013) High-throughput fluorescent-based NKCC functional assay in adherent epithelial cells BMC Cell Biol. 14, 16
30. Felix, J.-P., Williams, B.-S., Priest, B.-T., Brochu, R.-M., Dick, I.-E., Warren, V.-A., Yan, L., Slaughter, R.-S., Kaczorowski, G.-J., Smith, M.-M., and Garcia, M.L. (2004) Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes Assay Drug Dev. Technol. 2, 260-268
31. Vickery, R.-G., Amagasu, S.-M., Chang, R., Mai, N., Kaufman, E., Martin, J., Hembrador, J., OKeefe, M.-D., Gee, C., Marquess, D., and Smith, J.-A. (2004) Comparison of the pharmacological properties of rat Na(V)1.8 with rat Na(V)1.2a and human Na(V)1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR(R) Recept. Channels 10, 11-23
32. Chen, M.-X., Gatfield, K., Ward, E., Downie, D., Sneddon, H.-F., Walsh, S., Powell, A.-J., Laine, D., Carr, M., and Trezise, D. (2015) Validation and Optimization of Novel High-Throughput Assays for Human Epithelial Sodium Channels J. Biomol. Screening 20, 242-253 10.1177/1087057114552399
33. Clare, J.-J. (2010) Targeting voltage-gated sodium channels for pain therapy Expert Opin. Invest. Drugs 19, 45-62
34. Goldberg, Y.-P., MacFarlane, J., MacDonald, M.-L., Thompson, J., Dube, M.-P., Mattice, M., Fraser, R., Young, C., Hossain, S., Pape, T., Payne, B., Radomski, C., Donaldson, G., Ives, E., Cox, J., Younghusband, H.-B., Green, R., Duff, A., Boltshauser, E., Grinspan, G.-A., Dimon, J.-H., Sibley, B.-G., Andria, G., Toscano, E., Kerdraon, J., Bowsher, D., Pimstone, S.-N., Samuels, M.-E., Sherrington, R., and Hayden, M.-R. (2007) Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations Clin. Genet. 71, 311-319
35. Fischer, T.-Z. and Waxman, S.-G. (2010) Familial pain syndromes from mutations of the NaV1.7 sodium channel Ann. N. Y. Acad. Sci. 1184, 196-207
36. Hille, B. (1972) The permeability of the sodium channel to metal cations in myelinated nerve J. Gen. Physiol. 59, 637-58
37. Ulbricht, W. (2008) Effects of veratridine on sodium currents and fluxes Rev. Physiol. Biochem. Pharmacol. 133, 1-54
38. Bregman, H., Berry, L., Buchanan, J.-L., Chen, A., Du, B., Feric, E., Hierl, M., Huang, L., Immke, D., Janosky, B., Johnson, D., Li, X., Ligutti, J., Liu, D., Malmberg, A., Matson, D., McDermott, J., Miu, P., Nguyen, H.-N., Patel, V.-F., Waldon, D., Wilenkin, B., Zheng, X.-M., Zou, A., McDonough, S.-I., and DiMauro, E.-F. (2011) Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain J. Med. Chem. 54, 4427-4445
39. Chevrier, P. 2004, Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine Br. J. Pharmacol. 142 (3) 576-584
40. Nau, C. 1999, Stereoselectivity of bupivacaine in local anesthetic-sensitive ion channels of peripheral nerve Anesthesiology 91 (3) 786-795
41. Estacion, M. 2010, Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability Mol. Pain 6, 35
42. McNulty, M. M. 2004, State-dependent mibefradil block of Na+ channels Mol. Pharmacol. 66, 1652-1661
43. Fischer, T. Z. 2009, A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia Ann. Neurol. 65 (6) 733-741
44. Sheets, P. L. 2008, Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2 R)-2-(acetylamino)- N -benzyl-3-methoxypropanamide], lidocaine, and carbamazepine J. Pharmacol. Exp Ther. 326 (1) 89-99
45. Akiba, I1, Seki, T., Mori, M., Iizuka, M., Nishimura, S., Sasaki, S., Imoto, K., and Barsoumian, E. L. (2003) Stable expression and characterization of human PN1 and PN3 sodium channels Recept. Channels 9 (5) 291-299
46. Zhang, J.-H., Chung, T.-D., and Oldenburg, K.-R. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays J. Biomol. Screening 4, 67-73
47. Bhave, G., Lonergan, D., Chauder, B. A., and Denton, J. S. (2010) Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities Future Med. Chem. 2 (5) 757-774
48. Ramos-Hunter, S. J., Engers, D. W., Kaufmann, K., Du, Y., Lindsley, C. W., Weaver, C. D., and Sulikowski, G. A. (2013) Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activators Bioorg. Med. Chem. Lett. 23 (18) 5195-5198
49. Wen, W., Wu, W., Romaine, I. M., Kaufmann, K., Du, Y., Sulikowski, G. A., Weaver, C. D., and Lindsley, C. W. (2013) Discovery of molecular switches within a GIRK activator scaffold that afford selective GIRK inhibitors Bioorg. Med. Chem. Lett. 23 (16) 4562-4566
50. Wen, W., Wu, W., Weaver, C. D., and Lindsley, C. W. (2014) Discovery of potent and selective GIRK1/2 modulators via molecular switches within a series of 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)ureas Bioorg. Med. Chem. Lett. 24 (21) 5102-5106